References to Primary Literature
- BAGSHAWE KD: Antibody directed enzymes revive anticancer prodrug concept. Br. J. Cancer (1987) 65:531–532.
- RG MELTON, KNOX RJ, TA CONNORS: Antibody-directed enzyme prodrug therapy (ADEPT). Drugs of the Future (1996) 21:167–181.
- BAGSIIAWE KD, SIIARMA SK, SPRINGER CJ, ANTONIW P: Antibody directed enzyme prodrug therapy: a pilot scale clinical trial. Tumor Targeting (1995) 1:17–30.
- MATSUMURA Y, MAEDA H: A new concept for macro-molecular therapeutics in cancer chemotherapy. Can-cer Research (1966) 46:6387–6392.
- DUNCAN R, SPREAFICO F: Polymer conjugates: pharma-cokinetk considerations for design and development. Clin. Fharmacokinetics (1994) 27:290–306.
- O'HARE KB, DUNCAN R, STROHALM J, KOPECKOVA P,KOPECEK K, ULBRICH K: Macromolecular prodrugs con-taining doxorubicin and melanocyte stimulating hor-mone: in vitro and in vivo evaluation against murine melanoma. Drug Targeting (1993) 1:217–230.
- FRITZBERG AR, BEAUMIER PL, BOTTINO 13J, RENO JM: Approaches to improved antibody and peptide medi-ated targeting for imaging and therapy of cancer. J. Controlled Release (1994) 28:167–173.
- WALLACE PK, VALONE Eli, FANGER MW: Myeloid cell-tar-geted cytotoxicity of tutnorcells. In: Bispecfic Antibodies, MW Fanger (Ed.), RG Landes Company (1995):43–76.
- DURRANT L: Anti-idlotypic tumor immunotherapy. Tu-mor Targeting (1995) 1:65–66.
- PORTER JR, MILLICAN TA, MORPHY JR: Recent develop-ments in matrix metalloproteinase inhibitors. Exp. Opin. Ther. Patents (1995) 5:1287–1296.
- BAILL1E CT, WINSLET MC, BRADLEY NJ: Tumour vascula-ture - a potential therapeutic target Br. J. Cancer (1995) 72:257–267.
- PHILPOT M, BAGULEY BC, CHING L-M: Induction oftumour necrosis factor-a by single and repeated doses of the antittunour agent 5,6-dimethybtanthenone-4-acetic acid. Cancer Chemother. Pharmacol. (1995) 36:143–148.
- RHYU MS: Telomeres, telomerase and immortality. J.National Cancer Ins, (1995) 87:884–894.
- TODOROV P, CARIUK P, MCDEVITT T, COLES B, FEARONK, TISDALE M: Characterisation of a cancer cachetic factor. Nature (1996) 379:739–742,
- DOUGLAS JT, CURIEL DT: Targeted gene therapy. Tumor Targeting (1995) 1:67–84.
- CONNORS TA: The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Therapy (1995) 2:1–9.
- Nutrition and Cancer. GRIFFITHS K, ALDERCREUTZ H, BOYLE P, DENTS L, NICHOLSON RI, MORTON MS (Eds.), Isis Medical Media, Oxford (1996).
- WATTENBERG LW: Prevention, Therapy. Basic science and the resolution of the cancer problem. Cancer Re-search (1993) 53:5890–5896.
- MALARKEY K, BELIIAM CM, PAUL A, GRAIIAM A, MCLEES A, SCOTT PH, PEVIN R: The regulation of tyrosine kinase signalling pathways by growth factor and G-protein coupled receptors. Biochem. J. (1995) 309:361–375.
- GRAHAM SL: Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Exp. Opin. Ther. Patents (1995) 5:1269–1285.
- CROWELL PL, CHANG RR, REN Z, ELSON CE, GOULD MN: Selective inhibition of isoprenylation of 21-26 ItDa proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem. (1991) 266:17679–17685.
- DOMIN J, HIGGINS T, ROZENGURT E: Preferential inhibition of platelet derived growth factor stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid./ Biol. Chem. (1994) 269:8260–8267.
- European Cancer News (1996) 9:4–12.
References to Patent Literature
- CANCER RESEARCH CAMPAIGN, W08807378 (1988).
- BRISTOL-MYERS SQUIBB, EP-302473-A (1989).
- CESKOSLOVENSKA AKADEMIE VED., GB-8500209 (1985).
- FARMITALIA CARLO ERBA, W09313804 (1993).
- NIKKA WIIISKY DISTILLING CO. LTD., EP-657169-A (1995).
- INDENA SPA, EP-657169-A (1995).
- AMERICAN HEALTH FT)N., US5391568-A (1999).
- KOBE SEIKOJO KK, JP6329537-A (1995).
- ICl/ZENECA, W09515932 (1995).
- WARNER-LAMBERT CO., W09519970 (1995).
- MERCK & CO., INC., W09410138 (1994).
- GENENTECII, INC. etal., W09426723 (1994).
- KYOWA IIAKKO KOGYO CO. LTD. W09508542 (1995).